- Home
- KOSS vs ATNM Comparison
KOSS vs ATNM Comparison
Compare KOSS & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- ATNM
- Stock Information
- Founded
- KOSS 1953
- ATNM 2000
- Country
- KOSS United States
- ATNM United States
- Employees
- KOSS N/A
- ATNM N/A
- Industry
- KOSS Consumer Electronics/Appliances
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- KOSS Consumer Staples
- ATNM Health Care
- Exchange
- KOSS Nasdaq
- ATNM Nasdaq
- Market Cap
- KOSS 46.1M
- ATNM 46.5M
- IPO Year
- KOSS N/A
- ATNM N/A
- Fundamental
- Price
- KOSS $4.78
- ATNM $1.50
- Analyst Decision
- KOSS
- ATNM Strong Buy
- Analyst Count
- KOSS 0
- ATNM 4
- Target Price
- KOSS N/A
- ATNM $8.75
- AVG Volume (30 Days)
- KOSS 40.8K
- ATNM 1.3M
- Earning Date
- KOSS 05-08-2025
- ATNM 04-25-2025
- Dividend Yield
- KOSS N/A
- ATNM N/A
- EPS Growth
- KOSS N/A
- ATNM N/A
- EPS
- KOSS N/A
- ATNM N/A
- Revenue
- KOSS $12,289,961.00
- ATNM N/A
- Revenue This Year
- KOSS N/A
- ATNM N/A
- Revenue Next Year
- KOSS N/A
- ATNM N/A
- P/E Ratio
- KOSS N/A
- ATNM N/A
- Revenue Growth
- KOSS N/A
- ATNM N/A
- 52 Week Low
- KOSS $2.27
- ATNM $1.03
- 52 Week High
- KOSS $18.73
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- KOSS 39.52
- ATNM 54.24
- Support Level
- KOSS $4.64
- ATNM $1.66
- Resistance Level
- KOSS $5.95
- ATNM $2.41
- Average True Range (ATR)
- KOSS 0.37
- ATNM 0.23
- MACD
- KOSS -0.00
- ATNM 0.03
- Stochastic Oscillator
- KOSS 10.69
- ATNM 27.20
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.